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Immunomodulators of pathogens frequently affect multiple cellular targets, thus preventing recognition by different
immune cells. For instance, the K5 modulator of immune recognition (MIR2) from Kaposi sarcoma–associated
herpesvirus prevents activation of cytotoxic T cells, natural killer cells, and natural killer T cells by downregulating
major histocompatibility complex (MHC) class I molecules, the MHC-like molecule CD1, the cell adhesion molecules
ICAM-1 and PECAM, and the co-stimulatory molecule B7.2. K5 belongs to a family of viral- and cellular-membrane-
spanning RING ubiquitin ligases. While a limited number of transmembrane proteins have been shown to be targeted
for degradation by this family, it is unknown whether additional targets exist. We now describe a quantitative
proteomics approach to identify novel targets of this protein family. Using stable isotope labeling by amino acids, we
compared the proteome of plasma, Golgi, and endoplasmic reticulum membranes in the presence and absence of K5.
Mass spectrometric protein identification revealed four proteins that were consistently underrepresented in the
plasma membrane of K5 expression cells: MHC I (as expected), bone marrow stromal antigen 2 (BST-2, CD316),
activated leukocyte cell adhesion molecule (ALCAM, CD166) and Syntaxin-4. Downregulation of each of these proteins
was independently confirmed by immunoblotting with specific antibodies. We further demonstrate that ALCAM is a
bona fide target of both K5 and the myxomavirus homolog M153R. Upon exiting the endoplasmic reticulum, ALCAM is
ubiquitinated in the presence of wild-type, but not RING-deficient or acidic motif–deficient, K5, and is targeted for
lysosomal degradation via the multivesicular body pathway. Since ALCAM is the ligand for CD6, a member of the
immunological synapse of T cells, its removal by viral immune modulators implies a role for CD6 in the recognition of
pathogens by T cells. The unbiased global proteome analysis therefore revealed novel immunomodulatory functions of
pathogen proteins.
Citation: Bartee E, McCormack A, Fru ¨h K (2006) Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2(10): e107. DOI: 10.
1371/journal.ppat.0020107
Introduction
Viral and bacterial virulence often correlates with the
pathogen’s ability to modulate the host’s immune response.
One pathway that is frequently targeted by intracellular
pathogens, particularly viruses, is antigen presentation by
major histocompatibility complex (MHC) class I molecules.
By interfering with MHC I expression, transport, or peptide
loading, viruses become invisible to cytotoxic T cells.
Interestingly, many viral gene products that interfere with
MHC I also target other immunologically relevant host cell
proteins. For instance, US3 and US11 of human cytomega-
lovirus affect surface expression of both MHC I and MHC II
[1,2]. The murine cytomegalovirus protein m152 causes
mislocalization of both MHC I and Rae-1, an unrelated
molecule that is a ligand for the activating receptor NKG2D
found on natural killer cells and T cells [3,4]. Finally, the HIV-
1 proteins nef and vpu both downregulate MHC I and the T
cell co-receptor CD4 [5–8].
This multi-functionality is likely advantageous for the virus
since it interferes with recognition by different immune cells
and might counteract negative side effects of MHC I
downregulation such as activation of natural killer cells.
These observations, however, also raise the question of
whether the currently known host cell proteins are the only
targets of a given viral immune regulator or whether
additional targets exist. To address this question experimen-
tally, we selected the K5 protein of Kaposi sarcoma–
associated herpesvirus (KSHV), a particularly promiscuous
member of a family of viral immune modulators. KSHV
encodes two homologous members of the K3 family of viral
immune modulators, K5 and K3 [9,10]. These proteins display
an amino-terminal RING-CH domain facing the cytoplasm
followed by two membrane-traversing domains, resulting in a
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modulators are also found in several poxviral genomes
[12,13] and are most likely derived from host genes since
many eukaryotic organisms, including humans, contain
similar proteins, termed membrane-associated RING-CH
(MARCH) proteins, or c-MIR [14,15]. Both viral and mamma-
lian members of this family act as RING-type ubiquitin ligases
(RING-E3s) and mediate the ubiquitination of lysines or
cysteines in the cytoplasmic tail of transmembrane proteins
[16,17]. In most cases, ubiquitination occurs post–endoplas-
mic reticulum (ER), and ubiquitinated transmembrane
proteins are endocytosed, sorted to multivesicular bodies
(MVBs), and degraded in lysosomes [9,10,12,14,18]. ER-
associated proteasomal degradation has also been observed
for the K3 protein of murine herpesvirus 68 [16] and for some
substrates of KSHV-K5 [19].
All viral K3 family proteins studied so far, and two of the
human MARCH proteins, target MHC I for degradation.
Several K3 family proteins target other immunoreceptors in
addition to MHC I. For example, K5 also downregulates CD1,
ICAM-1, PECAM, and B7.2 [19–22], and M153R also targets
CD4 [12]. While the rules for substrate selection have yet to be
established, it seems evident that this protein family has
evolved to target subsets of transmembrane proteins. These
proteins are thus an excellent model for viral immune
modulators that have more than one cellular target. In
addition, these proteins are representative for other ubiq-
uitin ligases that target certain groups of proteins, not all of
which might be known [23].
K5 was initially identiﬁed by screening the KSHV genome
for gene products inhibiting MHC I expression [9]. Further
targets for K5 were then revealed by monitoring the
expression of a small set of cell surface proteins, particularly
those involved in T cell recognition of infected cells [19–21].
These experiments, however, did not rule out that expression
of other cellular proteins is inhibited by K5. Ideally, to
determine whether additional targets exist, the entire cell
proteome would be studied in the presence or absence of K5.
A method to absolutely quantify the entire protein comple-
ment of a cell has yet to be developed; however, recent
advances in quantitative proteomics using stable isotope
labeling allow the relative quantiﬁcation of proteins in
different samples by mass spectrometry (MS) [24].
In cell culture, the preferred method of comparative
quantitative proteomics is to metabolically incorporate heavy
or light forms of speciﬁc amino acids. This technique is known
as stable isotope labeling with amino acids in cell culture
(SILAC) [25,26]. SILAC incorporates naturally occurring
amino acids (C
12 and N
14) into one sample and isotopically
labeled amino acids (C
13 and N
15) into another sample. The
ratio of the ‘‘light’’ to ‘‘heavy’’ peptide can then be determined
upon MS analysis of the combined samples. SILAC has been
successfully used in yeast, plant, and mammalian cells to
measure relative protein abundance [27–29].
K5 is a transmembrane protein that localizes to the ER,
Golgi, and plasma membranes [11,19]. Since K5 is known to
degrade other transmembrane proteins, we focused on
identifying proteins that were reduced upon K5 expression
in ER, Golgi, and plasma membrane fractions. In three
independent repeat experiments we observed that MHC I,
activated leukocyte cell adhesion molecule (ALCAM), bone
marrow stromal antigen 2 (BST-2), and Syntaxin-4 were
consistently reduced in plasma membranes of K5-expressing
cells, whereas only K5 itself was increased in any fraction.
While reduced MHC I expression was expected, none of the
other proteins were previously known to be affected by K5.
Importantly, downregulation of each of these proteins by K5
was conﬁrmed in independent experiments and by inde-
pendent methods, thus validating the quantitative proteomics
approach as a new method for identifying cellular proteins
affected by viral immunomodulators.
Results
Membrane Preparation and Mass Spectrometric Analysis
Since all previously described targets of K5 were type I
transmembrane glycoproteins, we hypothesized that novel
targets of K5 were most likely to be found in the membrane
fraction. Most targets of K5 are ubiquitinated in a post-ER
compartment and then sorted to endosomes in a clathrin-
dependent process [30]. We recently showed, however, that
newly synthesized CD31/PECAM is degraded by K5 prior to ER
exit by ER-associated proteasomal degradation [19]. It is thus
conceivable that novel targets could be eliminated from either
the plasma membrane or from intracellular membranes,
particularly within the exocytic pathway. For these reasons,
we wanted to measure changes in the proteome of the plasma
membrane, the Golgi membrane, and the ER membrane.
To measure changes in the membrane proteome we used
stable-isotope-labeled amino acids coupled with mass spec-
trometric analysis. Since isotope labeling incorporates differ-
entially weighted tags directly into proteins, this method
allows the fractionation of membranes after combination of
samples, thus minimizing variation due to sample prepara-
tion. The weight differential is then used to discriminate
between peptides derived from each sample and to determine
relative protein abundance by mass spectrometric analysis.
Previous work has demonstrated that isotopically labeled
amino acid analogs are indistinguishable from the natural
product with respect to supporting cell growth in tissue
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Synopsis
Viral immune modulators often target multiple cellular proteins for
destruction. Presumably, this strategy enables viral pathogens to
optimize evasion of multiple immune responses. To systematically
identify such host cell targets in an unbiased fashion, Bartee et al.
applied recently developed quantitative proteomics methods to
identify novel targets for K5. K5 belongs to a family of viral ubiquitin
ligases found in gamma-herpesviruses and poxviruses that target
multiple cellular transmembrane proteins for destruction. Using
stable isotope labeling combined with tandem mass spectrometry,
the authors compared the abundance of proteins in membrane
preparations from cells that expressed K5 to that in cells without K5.
In their experiments, three novel membrane proteins (BST-2,
Syntaxin-4, and ALCAM) were consistently found in lower abun-
dance in K5-expressing cells. Importantly, the authors were able to
confirm the K5-dependent downregulation of all of these proteins in
independent experiments and by independent methods. ALCAM
was chosen for a more in-depth analysis to firmly demonstrate that
this protein is downregulated by K5 in a manner similar to other
known targets. This proof-of-principle study demonstrates that
novel targets of viral immune modulators can be identified with
quantitative proteomics.culture [25]. For our experiments, we added both N
15/6C
13-
labeled leucine and 2N
15/6C
13-labeled lysine to HeLa cells.
Since trypsin cleaves after lysines, and almost 70% of
predicted tryptic peptides in the human genome contain at
least one leucine, this double labeling procedure ensures that
most tryptic peptides will contain at least one isotopic amino
acid [26]. HeLa cells were grown in labeling medium for 5 d
prior to expression of K5 via adenovirus transduction. Due to
rapid doubling of HeLa cells, this time frame allowed for the
complete incorporation of isotopic amino acids (unpublished
data). Control cells were grown in medium containing natural
amino acids and transduced with the same multiplicity of
infection of control adenovirus. K5-mediated downregulation
of MHC I was conﬁrmed by ﬂow cytometry 24 h post-
infection (unpublished data). To minimize variation due to
biochemical procedures, plasma membrane, ER, and Golgi
fractions were generated by sucrose gradient separation after
lysis of the combined labeled and unlabeled cells (Figure 1).
To further control for technical and biological variation, we
repeated each experiment three times. Tryptic peptides from
the resulting fractions were separated by two sequential
chromatography steps (strong cation and reverse phase) prior
to analysis by MS using an LCQ ion-trap instrument in data-
dependent MS/MS mode. Tandem mass spectra of dissociated
peptides were used to search the human subset of the UniProt
database, which was spiked with the viral K5 sequence using
SEQUEST [31]. To discriminate true assignments of MS/MS
spectra to peptide sequences from false assignments, we
applied PeptideProphet software using a score of 0.85 as the
cutoff value for each identiﬁed peptide [32].
For each fraction we identiﬁed 500–700 unique proteins by
at least one peptide in at least one experiment (Figure 2A). Of
these, 100–150 proteins were identiﬁed in all three experi-
ments, a ﬁnding that is consistent with previous reports [33].
To validate the membrane preparations, we analyzed proteins
that were identiﬁed in all three replicate experiments of each
fraction with respect to their subcellular localization (Figure
2 B ) .T h ep l a s m am e m b r a n ef r a c t i o nc o n t a i n e dal a r g e
percentage of predicted cell surface proteins. The ER and
the Golgi fraction contained both bona ﬁde ER- and Golgi-
resident proteins and many plasma membrane or trans-
membrane proteins, presumably en route to the cell surface.
In addition, all fractions contained signiﬁcant numbers of
proteins predicted to localize to other intracellular organelles
such as the nucleus, cytoplasm, or mitochondria. These
proteins are likely derived from contaminating protein
fractions. Since K5 is not expected to affect proteins in these
compartments, these proteins serve as internal controls.
Differentially Expressed Proteins
To identify proteins whose expression was altered by K5,
we analyzed proteins identiﬁed in all three experiments
using the program ASAPRatio [34]. ASAPRatio calculates
expression ratios based on peak intensities such as those
shown in Figure 2C. Since a 1.5-fold cutoff was previously
shown to reﬂect a signiﬁcantly different protein level [26],
we considered proteins differentially expressed if they
displayed higher than a 1.5-fold change in either direction.
However, instead of limiting our analysis to proteins
identiﬁed by multiple peptides in a single experiment as
done previously [26], we accounted for biological variation
by focusing on proteins that changed in the same direction
in all three experiments, regardless of the number of
peptides identiﬁed in either experiment. Using these
criteria, only one protein changed in the ER and Golgi
fractions. This protein was K5 itself, which was scored as
Figure 1. Schematic Representation of the SILAC Labeling and Purification Protocol
HeLa cells were grown for 5 d in labeling medium to ensure complete labeling. They were then infected with either adenovirus vector (light sample) or
adenovirus-expressing K5 (heavy sample). Then 24 h post-infection, cells were harvested and counted, and equal numbers of cells combined. Samples
were lysed in a Dounce homogenizer and unlysed cells removed by centrifugation. Membrane and soluble proteins were separated by centrifugation.
The membrane pellet was resuspended, and different membrane fractions were separated over a discontinuous sucrose gradient. The bands
corresponding to the plasma membrane (PM), Golgi, and ER fractions were removed and the proteins pelleted. The resulting pellet was then washed
with sodium carbonate to remove non-integral membrane proteins, followed by ammonium bicarbonate to remove salts and other impurities. The final
pellet was resuspended in 8 M urea and digested with trypsin for MS/MS analysis.
DOI: 10.1371/journal.ppat.0020107.g001
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(A) Approximately 500–700 proteins were identified by at least one peptide in each fraction; however, fewer than 150 proteins per fraction were
identified in all three replicates. Of these, only five proteins changed more than 1.5-fold in the plasma membrane (PM) fraction, while only one protein
changed more than 1.5-fold in all three replicates of either the Golgi or ER fractions.
(B) Proteins present in all three replicates of each fraction were analyzed for their predicted subcellular distribution using annotations in the Swiss-Prot
proteomics database.
(C) Comparison of signal intensities obtained for selected peptides from the indicated proteins. The red line indicates the actual raw data recovered
from the mass spectrometer; the blue line is a hypothetical best fit line drawn to help analyze elution time of the light and heavy peptides. The orange
arrows indicate the time at which the initial MS/MS scan was initiated. Peptides derived from unaffected proteins, such as CD44, display a similar
intensity for both the light and heavy isotopes. Peptides derived from differentially expressed proteins, such as BST-2, show clearly different intensity
peaks for the light and heavy peptides. Note the slightly different scale for intensity of each peptide.
DOI: 10.1371/journal.ppat.0020107.g002
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samples. K5 was also scored as upregulated in the plasma
membrane fraction of K5-expressing cells. Additionally, four
proteins were downregulated in all three plasma membrane
samples (Figure 2A; Table 1). Among this list were peptides
mapping to the HLA-A01 allele, which were present in
signiﬁcantly lower amounts in the plasma membrane
fraction, but not in the ER or Golgi fractions. The lack of
statistically signiﬁcant MHC I downregulation in the ER
fraction is consistent with the observation that MHC I
assembly in the ER is not affected by K5 [9,10]. Since both
internal controls—transduced K5 as well as the K5 target
protein MHC I—were successfully identiﬁed as displaying
altered ratios, we anticipated that the three remaining
proteins in the plasma membrane fraction had a high
chance of being true positive results.
Each of these three proteins was not previously identiﬁed
as downregulated by K5: BST-2 (also known as HM1.24 and
CD316), Syntaxin-4, and ALCAM (CD166). To independently
conﬁrm the downregulation of these proteins, we obtained
speciﬁc antibodies for each and analyzed their expression in
the presence or absence of K5.
BST-2
BST-2 (Hs.118110) is a protein of largely unknown function
that has been implicated in normal as well as malignant B cell
differentiation [35,36]. BST-2 displays a very unusual top-
ology in that it contains both an amino-terminal trans-
membrane domain and a carboxy-terminal GPI linker [37].
Despite this topological difference and lack of relationship to
other K5 targets, BST-2 was consistently scored as the most
strongly underrepresented protein in K5-expressing cells
(Table 1). A dramatic reduction of BST-2 expression was
conﬁrmed in immunoblot of Ad-K5-infected HeLa cells,
whereas BST-2 was unaffected in Mock- or Ad-WT-infected
cells (Figure 3A). BST-2 expression was also strongly reduced
upon adenovirus-mediated expression of the human K5
homolog MARCH-VIII, but was less affected by the HIV
protein vpu, which recruits a cellular ubiquitin ligase. To
determine whether downregulation of BST-2 required the
ubiquitin ligase activity of K5, we transfected a catalytically
inactive mutant of K5 (K5-RING) that lacks two critical
cysteines in the K5-RING domain [38], and monitored BST-2
expression by immunoblot. While transiently transfected K5
was still able to downregulate BST-2, the K5-RING construct
Table 1. SILAC Analysis Yields Three Proteins Displaying Reproducibly Altered Protein Ratios
Category Protein Protein Ratio 6 Standard Deviation Unique Peptides
Experiment 1 Experiment 2 Experiment 3
Plasma membrane fraction ALCAM 2.04 6 0.24 2.59 6 0.96 1.68 6 0.19 (1) WKYEKPDGSPVFIAFR
(1, 2) (1, 3, 4) (1) (2) ALFLETEQLKK
(3) DLGNMEENKK
(4) WSLTLIVEGKPQIK
(5) SMIASTAITVHYLDLSLNPSGEVTR
BST-2 3.14 6 0.36 3.19 6 2.39 1.83 6 0.59 (1) ENQVLSVR
(1, 2, 3) (2, 3) (2) (2) KVEELEGEITTLNHK
(3) LQDASAEVER
Syntaxin-4 1.55 6 2.9 2.20 6 0.87 1.67 6 0.31 (1) AIEPQKEEADENYNSVNTR
(1, 2) (3, 4) (4) (2) VALVVHPGTAR
(3) KTQHGVLSQQFVELINK
(4) TQHGVLSQQFVELINK
MHC I 2.69 6 0.89 2.60 6 2.52 1.68 6 0.22 (1) DGEDQTELVETRPAGDGTHQK
(1, 2, 3, 4, 5) (1, 2, 3, 4, 7, 8, 9, 10, 11, 12) (1, 3, 5, 8) (2) RYLENGKETLQR
(3) YLENGKETLQR
(4) AQSQTDRVDLGTLR
(5) YTCHVQHEGLPEPLTLR
(6) YTCHVQHEGLPK
(7) GYHQYAYDGK
(8) GYHQYAYDGKDYIALK
(9) KGGSYSQAASSDSAQGSDVSLTACK
(10) THMTHHAVSDHEATLR
(11) HKWEAAHVAEQWR
(12) THVTHHPVSDHEATLR
KSHV-K5 0.00 6 0.00 0.26 6 0.05 0.30 6 0.19 (1) ALYAANNTR
(1) (1, 2, 3, 4) (3) (2) EEVGNEGIHPCACTGELDNNHPQCLSTWLTVSR
(3) TDLCAPTKKPVR
(4) VTVLPYR
ER fraction KSHV-K5 0.29 6 0.02 0.04 6 0.01 0.06 6 0.06 (1) ALYAANNTR
(1, 2) (1, 2) (2, 3, 4) (2) EEVGNEGIHPCACTGELDNNHPQCLSTWLTVSR
(3) TDLCAPTKKPVR
(4) VTVLPYR
Golgi fraction KSHV-K5 0.20 6 0.10 0.02 6 0.01 0.10 6 0.11 (1) ALYAANNTR
(1, 4) (1, 2) (1, 2, 3, 4) (2) EEVGNEGIHPCACTGELDNNHPQCLSTWLTVSR
(3) TDLCAPTKKPVR
(4) VTVLPYR
DOI: 10.1371/journal.ppat.0020107.t001
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expression (Figure 3B). Whether this reduction of BST-2
levels is a direct consequence of K5 ubiquitinating BST-2, or
an indirect consequence of the downregulation of other
proteins by K5, has not yet been established. However, these
experiments clearly conﬁrm that BST-2 protein levels are
reduced in K5-expressing cells and demonstrate that this
reduction requires catalytically active K5.
Syntaxin-4
The second protein identiﬁed as downregulated by K5 was
Syntaxin-4 (Hs.83734). Syntaxins belong to the target-mem-
brane-associated soluble N-ethylmaleimide fusion protein
attachment protein receptor (t-SNARE) family and are
responsible for correctly targeting and fusing intracellular
vesicles during transport [39]. Syntaxin-4 is a plasma
membrane–localized t-SNARE and mediates docking of
transport vesicles at the cell surface. Interestingly, Syntaxin-
6, a Golgi-localized t-SNARE, was previously observed to
associate with MARCH-II and MARCH-III, human homologs
of K5 [40,41]. To conﬁrm the reduction of Syntaxin-4 protein
in K5-expressing cells and to determine whether K5 or any of
the MARCH proteins associate with Syntaxin-4, we per-
formed immunoblots and immunoﬂuorescence experiments.
Reduced levels of Syntaxin-4 were observed in K5-expressing
HeLa cells, thus conﬁrming the mass spectrometric results
(Figure 4A). Interestingly, Syntaxin-4 levels were also reduced
upon expression of MARCH-VIII, but not upon expression of
vpu, suggesting that Syntaxin-4 is speciﬁcally targeted by
transmembrane RING-CH proteins. In immune ﬂuorescence
analysis of control cells, Syntaxin-4 was observed at the
plasma membrane. Expression of K5 led to a decrease in the
overall intensity of Syntaxin-4, but there was no obvious co-
localization (Figure 4B). In contrast, signiﬁcant co-local-
ization was observed upon transfection of all MARCH
proteins, except for MARCH-III and a naturally occurring
truncated splicing product to MARCH-IX (‘‘ RING’’ in
Figure 4B) [14]. Moreover, Syntaxin-4 seemed to be enriched
in the subcellular compartments corresponding to the
subcellular localization previously shown for the MARCH
proteins [14]. Thus, MARCH-IV and MARCH-VIII relocated
Syntaxin-4 to the Golgi and endosomes, respectively. Since
these results are similar to the previously reported binding of
Syntaxin-6 to MARCH-II and MARCH-III [40,41], it seems
highly likely that Syntaxin-4 also interacts with the MARCH
proteins with which it co-localizes.
The lack of co-localization of Syntaxin-4 with K5 could be
due to K5 degrading Syntaxin-4. However, Syntaxin-4 levels
are also reduced in MARCH-VIII-expressing cells, yet
MARCH-VIII clearly associates with Syntaxin-4. Alternatively,
it could be that only the minor fraction of K5 that trafﬁcs to
the plasma membrane [19] interacts with Syntaxin-4, whereas
the major, ER-localized population of K5 molecules is unable
to do so. To determine whether ER exit was the determining
factor for co-localization with Syntaxin-4, we generated
truncated versions of MARCH proteins that were unable to
leave the ER. Previous work has demonstrated that a carboxy-
terminal PDZ motif in MARCH proteins is required for their
forward transport since deletion of the ﬁnal four amino acids
resulted in ER retention of MARCH-II and MARCH-III
[40,41]. While we could not conﬁrm such a role for the
carboxy-terminal 45 amino acids in MARCH-VIII, we did
observe that MARCH-VIII truncated by 62 or 74 amino acids
was unable to exit the ER (Figure 4C). Importantly, ER-
resident MARCH-VIII mutants did not interact with Syntax-
in-4. This raised the possibility that Syntaxin-4 regulates ER
Figure 3. BST-2 Is Differentially Expressed in K5-Expressing Cells
HeLa cells were transduced with Ad-WT, Ad-K5, Ad-vpu, or Ad-MARCH-VIII. Then 24 h post-infection, cells were harvested and whole cell lysates were
analyzed for the abundance of BST-2 and MHC I by Western blotting. Note that BST-2 is highly glycosylated and runs as multiple bands. The high
molecular weight band marked with an asterisk is non-specific. Equal protein loading was confirmed by visualizing the ER resident chaperone Bap31 as
well as general protein staining with Ponceau red ([A], left). The intensity of each band was quantified using densitometry ([A], right). The specificity of
BST-2 downregulation was confirmed by transfecting K5 or a catalytically inactive K5-RING mutant, which showed no effect on either MHC I or BST-2 (B).
The protein bands corresponding to BST-2 are more intense in (B) than in (A) because of longer exposure of the autoradiograph as well as variation in
electrophoretic separation. Note that the same lysates were analyzed in lanes 1–3 of the blots in both (A) and (B).
DOI: 10.1371/journal.ppat.0020107.g003
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differ between the D46 and D62 mutants. Small interfering
RNA knockdown of Syntaxin-4, however, had no effect on
MARCH-VIII localization (unpublished data), so we consider
this hypothesis unlikely. Therefore, we conclude that Syntax-
in-4 associates only with MARCH proteins that have left the
ER. These data also render it highly likely that Syntaxin-4
associates, at least transiently, with the minor fraction of
surface-expressed K5. This K5 fraction is not visible by
immune ﬂuorescence analysis, but can be detected by cell
surface biotinylation [19]. Our data further suggest that K5
and MARCH proteins not only interact with, but also degrade
syntaxins. Since syntaxins play a major role in vesicular
trafﬁc, the reduction of syntaxin levels could mislocalize
transmembrane proteins, which might facilitate their target-
ing for ubiquitination. Further work will be required to
address the role of syntaxins in the function of this protein
family.
ALCAM (CD166)
ALCAM (CD166, Hs.591293) is a type I transmembrane
glycoprotein of the Ig superfamily that is the ligand for the
scavenger receptor CD6 on T cells [42]. The ALCAM–CD6
interaction is part of the immunological synapse and is
considered a co-stimulatory signal involved in lymphocyte
activation and thymocyte development [43–45]. Using trans-
fection of a hemagglutinin epitope (HA)–tagged construct, we
conﬁrmed that K5 very efﬁciently eliminated ALCAM-HA
upon co-transfection (Figure 5A). Additionally, downregula-
tion of ALCAM from the cell surface was conﬁrmed by ﬂow
cytometry of HeLa cells transduced with Ad-K5. In contrast
to ALCAM, K5 did not alter surface expression of CD9 or
CD29 (Figure 5B). The co-stimulatory function of ALCAM
renders this molecule an attractive target for viral immune
modulators. To determine whether other viral K3 family
proteins target ALCAM, we transfected KSHV-K3 and the
myxomavirus homolog M153R and monitored ALCAM
expression by ﬂow cytometry. Interestingly, M153R clearly
reduced ALCAM surface levels, whereas the K3 protein, the
most closely related K5 homolog, did not affect ALCAM
(Figure 5C). This result is consistent with previous observa-
tions that K3 targets are limited to classical and nonclassical
MHC I–like molecules [9,10,20], whereas both K5 and M153
display broader substrate speciﬁcity [12,21,22]. Within the
MARCH family, MARCH-IV and MARCH-IX downregulated
ALCAM to a signiﬁcant degree, while a modest effect was
observed with MARCH-VIII (Figure 5C). The RING and
transmembrane domains of MARCH-IV and MARCH-IX are
highly homologous to each other, and this result is consistent
with previous observations showing that the range of
substrates for these two MARCH proteins overlaps with that
of K5 [14].
The catalytically inactive K5-RING construct [38], as well as
a K5 construct lacking acidic clusters in its carboxy-terminal
domain (K5DE12) [19,46], did not affect surface expression of
ALCAM (Figure 5C). These data suggest that downregulation
of ALCAM requires the ubiquitin ligase activity and proper
subcellular targeting of K5.
To investigate whether ALCAM downregulation occurs in
KSHV-infected endothelial cells, we took advantage of the
fact that K5 is not expressed in latently infected dermal
microvascular endothelial cells (DMVECs), but can be
induced upon addition of phorbol 12-myristate 13-acetate
(PMA), which activates the lytic cycle [19]. As shown
previously, PMA treatment reduced expression of MHC I
on the cell surface of KSHV-infected DMVECs, but not
uninfected DMVECs (Figure 5D). The mean ﬂorescence of
ALCAM was unchanged in latently infected DMVECs, but was
reduced approximately 2-fold upon PMA treatment. In
contrast, levels of CD81, a multiple transmembrane-spanning
plasma membrane protein that is elevated in latently infected
cells, did not change upon PMA treatment. Since PMA
treatment does not induce lytic gene expression, and hence
K5 expression, in all of the KSHV-infected cells [47], the
actual levels of downregulation of both MHC I and ALCAM
might be considerably higher in individual cells. The
correlation of ALCAM downregulation and K5 expression,
however, renders it highly likely that virally expressed K5 is
causing this effect.
Taken together, these data suggested that ALCAM is a bona
ﬁde substrate for the viral ubiquitin ligase K5. To conﬁrm
that ALCAM downregulation involved K5-dependent con-
jugation of ubiquitin, we transfected HeLa cells with ALCAM-
HA either in the presence or absence of Ad-K5. Ad-vpu, Ad-
K5DE12, and Ad-MARCH-VIII were used as controls. Then,
24 h post-transfection, cells were lysed and ALCAM precipi-
tated using an antibody against the HA epitope. Samples were
resolved on a SDS-PAGE gel, and the presence of ubiquiti-
nated ALCAM-HA was analyzed by immunoblotting with the
anti-ubiquitin antibody P4D1. In cells transfected with
ALCAM-HA alone, ubiquitinated ALCAM-HA was undetect-
able (Figure 6A). In the presence of K5, however, substantially
increased levels of ubiquitinated ALCAM-HA were observed,
consistent with K5-mediated ubiquitination of ALCAM.
Acidic motif–deleted K5 and HIV-vpu had no effect, whereas
MARCH-VIII slightly increased ALCAM-HA ubiquitination,
consistent with the slight downregulation of endogenous
ALCAM observed by ﬂow cytometry.
Depending on the subcellular localization of the ubiquiti-
nation reaction, K5 targets are degraded in lysosomes or by
the proteasome [19]. To determine which degradation system
was responsible for ALCAM degradation, we followed the
maturation and degradation of ALCAM-HA using pulse-
chase analysis in the presence of proteasomal inhibitors or
inhibitors of endosomal acidiﬁcation. In the absence of K5,
ALCAM-HA acquired complete resistance to endoglycosidase
H within 2 h post-labeling, indicating its intracellular
transport through the Golgi complex (Figure 6B). After
chasing for 8 h, ALCAM-HA levels remained high in control
cells, showing only a minor reduction due to endogenous
turnover. Expression of K5 did not alter ALCAM biosynthesis
or trafﬁcking through the Golgi; however, amounts of
endoglycosidase H–resistant ALCAM were signiﬁcantly re-
duced, consistent with a post-Golgi degradation mechanism.
K5-dependent degradation of ALCAM was inhibited by
inhibiting lysosomal acidiﬁcation with concanamycin A but
not by the proteasomal inhibitor MG132. A similar effect was
seen with ﬂuorescent microscopy analysis (unpublished data).
To determine whether ALCAM is targeted to lysosomes via
the MVB pathway, we co-transfected K5 with a dominant
negative version of the AAA-ATPase Vps4 (Vps4mut), which
prevents MVB formation [48]. Expression of dominant
negative Vps4 partially restored surface expression of both
MHC I and ALCAM measured using ﬂow cytometry, whereas
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SILAC Analysis Yields Novel K5 SubstrateFigure 4. K5 Causes Downregulation but Not Relocalization of Syntaxin-4
(A) HeLa cells were transduced with Ad-WT, Ad-K5, Ad-vpu, or Ad-MARCH-VIII. Then 24 h post-infection, cells were harvested and whole cell lysates were
analyzed as in Figure 3, except that antibodies specific for Syntaxin-4 were used. Expression of K5 resulted in a moderate but reproducible reduction of
Syntaxin-4 levels.
(B) To determine if K5 or MARCH proteins caused a relocalization of Syntaxin-4, HeLa cells were transfected with C-terminally FLAG-tagged versions of
the E3 enzymes shown. Cells were then analyzed for the location of Syntaxin-4 (using an Alexa Fluor 594–conjugated secondary antibody, shown as red)
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SILAC Analysis Yields Novel K5 Substratewild-type Vps4 had only a minor effect (Figure 6C). Taken
together, these data indicate that K5 ubiquitinates ALCAM in
a post-ER compartment, thus triggering ubiquitin-mediated
endocytosis and targeting of ALCAM for lysosomal destruc-
tion via the MVB pathway. Since this mechanism is similar to
that of other K5 targets, we conclude that ALCAM is a novel
substrate for K5 as well as a target for M153R. Thus, we
present a novel approach for the systematic identiﬁcation of
substrates for transmembrane ubiquitin ligases as well as viral
immune modulators targeting membrane proteins.
Discussion
The goal of this work was to systematically search for
novel targets of viral immune modulators. To this end, we
applied SILAC, a quantitative proteomics method based on
metabolic isotope labeling. Until now, the SILAC method
was mainly used for global comparative proteomics experi-
ments expected to yield a relatively large number of
changes, such as the comparison of cell surface proteins
from T helper 1 versus T helper 2 cells [49], differential
protein secretion from cancer versus normal cells [50],
proteins associated with stimulation of a given receptor [51],
or changes in substrates trapped by a mutant protease
complex upon stress activation [52]. To our knowledge,
however, this is the ﬁrst time SILAC has been used in an
experiment where only a few protein changes were
expected. A major challenge for this approach was to
identify true changes among the high rate of false positives
that are caused by false peptide identiﬁcation, inaccurate
measurements of peptide intensity, or biological variation
arising during the labeling procedure. For these reasons,
protein quantitation in SILAC experiments is usually limited
to proteins that are identiﬁed by two or more peptides (e.g.,
[52]). This allows conﬁrmation of each peptide by a second
peptide from the same protein, thus raising conﬁdence that
calculated protein ratios are accurate. This approach,
however, severely limits proteome coverage, particularly
for low abundance proteins that are often identiﬁed by only
one peptide. For this reason we sought to include all
identiﬁed proteins in our analysis regardless of how many
peptides were used in their identiﬁcation. Inclusion of single
peptide identiﬁcations raised the background for individual
experiments to the point that it was impossible to discrim-
inate between true positives and false positives purely by a
fold-change cutoff (unpublished data). By analyzing three
biological replicate experiments, we were able to identify
true positives. The use of three replicates sets a high
threshold and might exclude potential substrates. However,
upon lowering the stringency (either two out of three
experiments or several peptides in one experiment), we were
unable to conﬁrm additional targets from a few selected
candidates, suggesting a dramatic increase in the false
positive rate (unpublished data). In contrast, using three
replicates resulted in 100% speciﬁcity.
The rate of false negatives—the proteins that were affected
by K5 but were eliminated by these selection criteria—is
difﬁcult to gauge since only a few of the known K5 targets
(MHC I and ICAM-1) are present in HeLa cells. No peptides
derived from ICAM-1 were ever identiﬁed, probably since
ICAM-1 is expressed at low levels in this cell type unless
induced by pro-inﬂammatory stimuli. A better estimate of the
false negative rate could potentially be obtained by analyzing
other cell types, such as B cells and endothelial cells that
express high levels of multiple K5 targets. The sensitivity of
the method is therefore presently unknown. However, since
only a fraction of the membrane proteome was identiﬁed
here, it is likely that additional targets for K5 will be revealed
by improved protein identiﬁcation, improved analysis meth-
ods, or improved enrichment of the target proteome.
Using speciﬁc antibodies as well as epitope tagging, we
conﬁrmed the K5-dependent reduction in protein abundance
for BST-2, Syntaxin-4, and ALCAM in independent experi-
ments. Of these proteins, only BST-2 was unrelated to protein
families previously shown to interact with or be targeted by
the MARCH family or K3 family proteins. Downregulation of
BST-2 required the ubiquitin ligase function of K5, suggest-
ing that the reduced expression of BST-2 is linked to the
enzymatic function of K5. However, we have not ruled out the
possibility that BST-2 levels are indirectly affected by another
protein that is targeted by K5. Thus, one of the limitations of
the SILAC approach is that it does not discriminate between
proteins that are targeted directly and those that are targeted
indirectly by the transmembrane ubiquitin ligases. This
limitation could possibly be overcome by combining the
SILAC analysis with proteomic analysis of ubiquitinated
proteins [53,54]. Further experiments will be needed to
determine whether BST-2 is a bona ﬁde target of K5 or
related molecules. If so, it could be that BST-2 plays an as yet
unknown role in immune defense.
The identiﬁcation of Syntaxin-4 by the SILAC method was
surprising for several reasons. First, the K5-induced changes
in Syntaxin-4 levels were relatively modest compared to
those for MHC I, ALCAM, or BST-2. This demonstrates that
even moderately changing proteins can be identiﬁed by
SILAC, provided these changes can be measured reprodu-
cibly. Second, previous observations with MARCH proteins
indicated that syntaxins interact with this protein family,
but evidence for degradation was not reported. Third,
Syntaxin-4 is quite different from the typical K5 substrates,
which mostly represent type I glycoproteins of the Ig
superfamily. In contrast, Syntaxin-4 is a type II trans-
membrane protein with a carboxy-terminal tail-anchor and
multiple coiled-coil domains. As discussed above for BST-2,
it might therefore be that K5 mediates degradation of
Syntaxin-4 through an indirect mechanism. However, the
co-localization of Syntaxin-4 with all MARCH proteins that
locate to post-ER compartments renders it likely that
Syntaxin-4 interaction is a general feature of the entire
protein family, including K5. Syntaxin-4 thus joins a
as well as the overexpressed E3 (using a FITC-conjugated anti-FLAG antibody, shown as green). Co-localization of Syntaxin-4 and the ubiquitin ligases is
revealed as yellow co-staining. While K5 did not co-localize with Syntaxin-4, several MARCH family proteins relocalized Syntaxin-4 to a MARCH-
containing compartment. A naturally occurring splice variant of MARCH-IX that lacks a complete RING domain and fails to exit the ER was unable to
relocalize Syntaxin-4.
(C) C-terminal truncation mutants of MARCH-VIII that failed to exit the ER do not co-localize with Syntaxin-4.
DOI: 10.1371/journal.ppat.0020107.g004
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SILAC Analysis Yields Novel K5 Substrategrowing list of vesicular trafﬁcking regulators interacting
with MARCH family or K3 family proteins. In addition to
the above-mentioned Golgi t-SNARE Syntaxin-6 that inter-
acts with MARCH-II and MARCH-III, this list includes the
COP-I adaptor protein PACS-2 [19] and the ER/cis-Golgi-
located adaptor protein Vap-A (R. Means and S. Lang,
personal communication). Either such interactions could
locate the RING-CH proteins to speciﬁc vesicular compart-
ments, or the RING-CH protein could interfere with the
function of the vesicular regulators. In the case of Syntaxin-
4, it is conceivable that downregulation of Syntaxin-4
reduces the exocytosis of certain proteins. For instance,
Syntaxin-4 is required for the secretion of insulin in
pancreatic beta cells [55]. One could therefore speculate
that, by degrading Syntaxin-4, KSHV prevents the secretion
of immune stimulatory chemokines or cytokines. Interest-
ingly, another membrane-associated RING ubiquitin ligase,
termed Staring, was previously shown to interact with,
Figure 5. K5 Downregulates ALCAM
(A) C-terminally HA-tagged ALCAM was co-transfected with K5 or control plasmid. Then 24 h post-transfection, cells were harvested and the abundance
of ALCAM-HA in each lysate was measured by Western blotting with anti-HA antibody.
(B) Cell surface expression of endogenous ALCAM in the presence or absence of K5 was determined by flow cytometry. HeLa cells were co-transfected
with K5 and a green fluorescent protein (GFP)–expressing plasmid to identify transfectants. Then 24 h post-transfection, cells were harvested and
stained with antibodies against MHC I, ALCAM, CD9, and CD29. Both vector (solid black) and K5-transfected (white) cells were gated for GFP-expressing
cells.
(C) ALCAM downregulation by K5-related proteins was determined by transfecting HeLa cells with viral K3 family members (K3 and M153R) and the
indicated human MARCH proteins. Also examined were mutant K5 proteins with enzymatically inactive RING-CH domains (K5-RING) or lacking acidic
residues implicated in subcellular targeting (K5DE12). Neither K5 mutant reduced ALCAM levels. KSHV K3 was unable to downregulate ALCAM, whereas
the myxomavirus M153R protein significantly reduced ALCAM surface expression. Two of the MARCH proteins, MARCH-IV and MARCH-IX, strongly
downregulated ALCAM, while MARCH-VIII showed a minimal effect.
(D) To determine whether ALCAM expression was affected by KSHV, latently infected immortalized DMVECs were treated with PMA to induce
expression of lytic genes including K5. Surface levels of either MHC I or ALCAM were measured by flow cytometry 24 and 48 h post-induction. CD81,
measured at 24 h, was used as a control. The ratio between the mean fluorescence intensity of infected and uninfected samples from these experiments
is shown as fold change on the right.
DOI: 10.1371/journal.ppat.0020107.g005
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SILAC Analysis Yields Novel K5 Substrateubiquitinate, and degrade Syntaxin-1 [56]. It is therefore
conceivable that the degradation of Syntaxin-4 by endoge-
nous MARCH proteins plays a role in the turnover of
Syntaxin-4, thus regulating exocytosis.
The ﬁnal novel protein identiﬁed by our SILAC screen was
ALCAM (CD166). Similar to other proteins downregulated by
K5, ALCAM is a type I glycoprotein of the Ig superfamily.
Several lines of evidence suggest that ALCAM is a bona ﬁde
target of K5. ALCAM downregulation required a functional
RING-CH domain and acidic motif in K5. Similar to other K5
target molecules, ALCAM was ubiquitinated and targeted to
lysosomes via the MVB pathway. Most likely, K5 ubiquitinates
ALCAM at the plasma membrane, resulting in ubiquitin-
mediated endocytosis and lysosomal destruction.
In addition, we observed that the myxomavirus protein
M153R downregulated ALCAM, likely by a similar mecha-
nism, although this has not been experimentally veriﬁed.
Previously, it was shown that M153R prevents T cell
recognition of myxomavirus-infected cells [13]. In addition,
Coscoy and Ganem demonstrated that K5-transfected B cells
do not stimulate T cells [21]. While the predominant reason
for this lack of T cell recognition is likely the downregulation
of MHC I from the cell surface, Coscoy and Ganem showed
that the elimination of B7.2 and ICAM-1 further reduces T
cell receptor (TCR) signaling [21]. It was thus concluded that
the combined effect of preventing both the primary signal via
the TCR and the co-stimulatory signals via LFA-1 and CD28,
the respective ligands of ICAM-1 and B7.2, minimizes T cell
activation by KSHV-infected B cells. Similar to LFA-1 and
CD28, ALCAM’s ligand, CD6, becomes an integral part of the
immunological synapse. Speciﬁcally, LFA-1 forms a ring
around the synapse, whereas CD28 and CD6 co-localize with
the TCR in the center of the synapse [43]. It is generally
believed that this supramolecular structure is required for the
sustained TCR engagement needed to generate the full
repertoire of T cell responses, including signal transduction,
cytokine generation, and cell proliferation [57]. Although the
function of CD6 has not been studied as extensively as that of
LFA-1 and CD28, there is accumulating evidence that the
CD6–ALCAM interaction contributes to formation and
function of the immunological synapse. It has been shown
that antibodies to CD6 activate T cells [58] and that CD6-
blocking antibodies or recombinant ALCAM-Fc proteins
inhibit T cell proliferation induced by dendritic cells [45].
Taken together, these observations strongly support the
notion that, by downregulating ALCAM, K5 and M153R
further optimize the ability of their respective viruses to
prevent T cell activation. Moreover, the ﬁnding that ALCAM
is eliminated by immune modulators from both herpesviruses
and poxviruses suggests that the ALCAM–CD6 ligand
receptor pair plays a previously unappreciated role in anti-
viral immunity.
In summary, our results validate the use of quantitative
proteomics to identify new substrates of viral and cellular
immune modulators. In addition to identifying this speciﬁc
class of transmembrane ubiquitin ligases, it is conceivable
that this approach can be used to identify additional targets
for any viral proteins that are known to reduce the
abundance of their host cell target molecules. Since many
viral proteins are thought to be multi-functional, such a
systematic, unbiased search for novel host cell targets could
help to reveal new functions of viral proteins. This
proteomics approach can also be used to ﬁnd novel targets
for cellular proteins that degrade a speciﬁc set of targets. In
particular, novel substrates for cellular ubiquitin ligases can
potentially be found this way. Since ubiquitin ligases are one
of the most abundant gene families in the human genome, it
is likely that almost every protein in the human genome is
regulated by one or more ubiquitin ligases. Identifying the
ligase–substrate relationship will be a daunting but important
task in unraveling the regulatory networks that govern
cellular functions. Novel approaches, as the one described
here, are likely to aid this process.
Figure 6. Ubiquitination and Lysosomal Degradation of ALCAM in the
Presence of K5
(A) Ubiquitination of ALCAM was examined by co-transfection of HeLa
cells with ALCAM-HA as well as the indicated E3 enzymes. Then 24 h
post-transfection, cells were lysed in 1% CHAPS, and ALCAM-HA was
immunoprecipitated using anti-HA antibody. Samples were resolved on
an 8% SDS-PAGE gel, transferred to PVDF, and immunoblotted (WB) with
the anti-ubiquitin (Ubi) antibody P4D1 (top) or anti-HA (bottom).
Ubiquitinated ALCAM was visible upon co-transfection of K5 and
MARCH-VIII, but not with the inactive K5DE12 mutant and the unrelated
HIV immune modulator vpu.
(B) To determine whether ubiquitinated ALCAM was degraded by
proteasomes or in lysosomes, the fate of newly synthesized ALCAM-HA
was determined by metabolic labeling for 10 min with S
35 Met/Cys and
chasing the label for the indicated times (hours) in the presence of the
indicated inhibitors. Following lysis, ALCAM-HA was immunoprecipitated
using the HA antibody and samples were treated overnight with
endoglycosidase H followed by electrophoretic separation. Note the
increased recovery of ALCAM at 8 h in the presence of the endosomal/
lysosomal proton pump inhibitor concanamycin A (ConA), but not in the
presence of the proteasomal inhibitor MG132 (50 lmol).
(C) Surface expression of ALCAM can be restored by overexpressing a
dominant negative version of the AAA-ATPase Vps4, which is essential
for targeting proteins to MVBs. HeLa cells were transfected as indicated
together with GFP to identify transfected cells. Then 24 h post-
transfection, cells were harvested and the surface expression of either
MHC I or ALCAM was analyzed using flow cytometry. The graph shows
the ratio of mean fluorescence intensity from K5-transfected cells to that
of control cells after gating for GFP. Data are averaged from three
separate experiments.
DOI: 10.1371/journal.ppat.0020107.g006
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Reagents and antibodies. Concanamycin A (Sigma, http://www.
sigmaaldrich.com) and MG132 (Sigma) were used at 50 nM and 50
lmol, respectively. The following reagents were obtained as in-
dicated: protein A/G beads (Santa Cruz Biotechnology, http://
www.scbt.com), ammonium bicarbonate (Sigma), sodium carbonate
(Fisher Scientiﬁc, https://www1.ﬁshersci.com), sucrose (Fisher Scien-
tiﬁc), and urea (Fisher Scientiﬁc). The following antibodies were used:
W6/32 (made in-house); anti-BST-2 (GeneTex, http://www.genetex.-
com); anti-Bap31 (Afﬁnity Bioreagents, http://www.bioreagents.com);
anti-Syntaxin-4, anti-CD9, and anti-ALCAM (BD Biosciences, http://
www.bdbiosciences.com); anti-Flag:FitC and anti-HA (Sigma); anti-
ubiquitin (clone P4D1 from Invitrogen, http://www.invitrogen.com);
anti-CD29 (University of Iowa Developmental Studies Hybridoma
Bank, http://www.uiowa.edu/;dshbwww); and goat anti-mouse Alexa
Fluor 594 (Molecular Probes, http://probes.invitrogen.com).
Plasmids and cloning. The following plasmids have been described
previously: K5 C-Flag/pUHD10–1, K5 RING C-Flag/pUDH10–1, K3/
pUDH10–1, M153R C-Flag/pUHD10–1, K5DE12 C-Flag/pUHD10–1,
plasmids expressing both Vps4 and Vps4mut, and all full-length
MARCH constructs in pUHD10–1 [12,14,38,59]. An adenoviral vector
expressing K5 C-Flag (Ad-K5) has been described previously [19].
Adenovirus-expressing vpu was a generous gift from A. Moses
(Vaccine and Gene Therapy Institute, United States).
A plasmid containing the ALCAM cDNA was a gift from G. Swart
(Radboud University, Netherlands). ALCAM-HA was generated from
this plasmid by PCR ampliﬁcation of the ALCAM open reading
frame. A C-terminal HA tag was added during the ampliﬁcation. The
PCR product was then digested using suitable enzymes and ligated
into the pUHD10–1 vector. MARCH-VIII truncation mutants (D46,
D62, and D74) were generated by PCR ampliﬁcation of the given
region. An N-terminal FLAG tag was added to each construct during
ampliﬁcation. Each PCR was then digested using suitable enzymes
and ligated into the mammalian-expressing vector pUHD10–1. An
adenoviral vector expressing MARCH-VIII was generated by cloning
the full-length open reading frame from MARCH-VIII into the
pShuttle vector (Stratagene, http://www.stratagene.com). Ad-MARCH-
VIII virus was generated by linearization, transfection, and ampliﬁ-
cation according to the manufacturer’s directions.
Culture conditions. Prior to labeling, HeLa-Tet Off cells were
grown in DMEM (Invitrogen) supplemented with 10% fetal calf serum
(Hyclone, http://www.hyclone.com) and 13 Pen/Strep (Invitrogen).
KSHV-infected DMVECs were established and maintained as pre-
viously described [47]. KSHV-infected DMVECs were used in experi-
ments when .90% of the cells expressed LANA-1.
Stable isotope labeling of HeLa cells. Cells were labeled with stable
isotopes using labeling medium (DMEM, Invitrogen) lacking the
amino acids L-lysine and L-leucine (prepared according to the
manufacturer’s protocol). Medium was supplemented with 10%
dialyzed fetal calf serum (Hyclone), 13 Pen/Strep (Invitrogen), and
either isotopically light L-lysine and L-leucine (Sigma) or isotopically
heavy L-lysine (U-13C6, 98%; U-15N2, 98%) and L-leucine (U-13C6,
98%; 15N, 98%) (Cambridge Isotope, http://www.isotope.com). Cells
were maintained in labeling medium for 6 d prior to initiation of the
experiment to insure complete labeling.
Preparation of samples for MS/MS analysis. Cells grown in labeling
medium were infected with either Ad-K5 (heavy-labeled cells) or
Ad-WT (light-labeled cells) at an MOI of 25. Then 24 h post-
infection, cells were harvested by scraping, washed twice in PBS,
resuspended in PBS containing 5 mM EDTA, and lysed by douncing.
Unlysed cells and debris were cleared from the lysate by
centrifugation for 5 min at 3,000 3 g. The cleared lysates were
separated into membrane and soluble fractions by centrifugation
for 30 min at 45,000 3 g. The membrane fraction was resuspended
in PBS by sonication and separated over a discontinous sucrose
gradient (2 M, 1.6 M, 1.25 M, 1.2 M, and 0.8 M) by centrifugation for
2.5 h at 25,000 rpm (Sorvall SW-28 rotor, http://www.sorvall.com).
The bands corresponding to the plasma membrane (0.8–1.2 M
interphase), Golgi (1.25–1.2 M interphase), and ER (1.6–1.25 M
interphase) fractions were removed, diluted 53 in Tris-EDTA (pH
8.0), and centrifuged for 30 min at 45,000 3 g to pellet the proteins
contained in each fraction. Pellets were washed for 30 min in 50
mM sodium bicarbonate (pH 11.5) and centrifuged for 30 min at
45,000 3 g, followed by a second wash in 50 mM ammonium
bicarbonate (pH 8.5) and further centrifugation for 30 min at
45,000 3 g. Final pellets were resuspended in 8.0 M deionized urea
and 50 mM ammonium bicarbonate (pH 8.5) and protein levels
quantitated using the Bio-Rad Protein Assay (Bio-Rad, http://www.
biorad.com). Samples were reduced with DTT (Sigma) and alkylated
with iodoacetamide (Sigma) prior to overnight digestion with
trypsin (Promega, http://www.promega.com).
Chromatography, MS, and informatics. Peptide mixtures were
analyzed by electrospray ionization tandem MS, coupled to two-
dimensional liquid chromatography, which was performed using a
modiﬁed version of the protocol described by Link and coworkers
[60]. Brieﬂy, 22 lg of sample was loaded onto an Opti-Pak capillary
SCX trap cartridge (Optimize Technologies, http://www.optimizetech.
com) and eluted stepwise (12.5, 25, 37.5, 50, 62.5, 75, 87.5, 100, 112.5,
125, 200, 300, or 450 mM ammonium acetate in 0.1% formic acid)
onto a reverse phase C-18 capillary column (180 lm 3 100 mm,
BioBasic-18; Thermo Electron, http://www.thermo.com). Peptides
were then eluted using an acetonitrile gradient (5%, 5 min; 5%–
40%, 75 min; 40%–90%, 10 min) into a ProteomeX LCQ Deca XP
Plus mass spectrometer (Thermo Electron) equipped with a low-ﬂow
(1 ll/min) electrospray source. The instrument was set to trigger data-
dependent MS/MS acquisition of the three most intense ions detected
during the MS survey scan when total ion current per MS survey scan
exceeded 5.0 3 10
5 counts.
Proteins were identiﬁed by analyzing tandem mass spectra with the
Sequest algorithm (Thermo Electron) as described by Yates et al. [61]
using the human subset of the UniProt/Swiss-Prot protein database
(UniProt release 5.1, http://www.expasy.org/sprot). The search results
were further analyzed using PeptideProphet [32]. SILAC ratios were
determined using the ASAPRatio algorithm [34]. Multiple peptides
derived from a single protein were included if PeptideProphet
probability was greater than or equal to 0.85. All positive results were
manually veriﬁed. The putative subcellular localization of proteins
was determined using the Swiss-Prot database.
Immune ﬂuorescence and ﬂow cytometry. Cells (1.5 3 10
4) were
plated on 15-mm coverslips (Fisher Scientiﬁc) and allowed to adhere
overnight prior to transfection. Following transfection, cells were
washed with PBS, ﬁxed with 2% paraformaldehyde for 20 min at
room temperature, and permeabilized with 0.2% Triton X-100 for 3
min at room temperature. Nonspeciﬁc binding sites were blocked
with 3% BSA and 0.5% ﬁsh gelatin in PBS for 30 min at 37 8C. The
ﬁxed cells were incubated overnight at 37 8C with primary antibody
diluted in blocking solution. Secondary and conjugated antibodies
were diluted in blocking solution and incubated with the cells for at
least 30 min at 37 8C. Cells were washed six times with PBS between
all antibody treatments. Slides were ﬁxed a second time in 2%
paraformaldehyde after the ﬁnal antibody treatment and washed
twice with PBS. Coverslips were then mounted on slides and covered
with Vectashield H-1200 þ DAPI (Vector Laboratories, http://www.
vectorlabs.com).
For ﬂow cytometry, cells were removed from tissue culture dishes
with 0.05% trypsin-EDTA (Invitrogen), washed with ice-cold PBS, and
incubated with appropriate antibody for 30 min at 4 8C. The cells
were washed with ice-cold PBS and either resuspended in ice-cold
PBS or incubated with PE-conjugated anti-mouse secondary antibody
(Dako, http://www.dako.com) and washed again before analysis with a
BD Biosciences FACSCalibur ﬂow cytometer.
Metabolic labeling, immunoprecipitation, and Western blotting.
HeLa cells were grown to 80% conﬂuency in 100-mm tissue culture
dishes and were transfected as above. At 24 h post-infection, cells
were incubated in serum-free and methionine-free medium for 30
min, and metabolically labeled with
35S-cysteine/
35S-methionine (300
lCi/plate; Amersham, http://www.amersham.com) for 20 min. After
labeling, cells were washed twice with PBS and the label was chased
for the indicated time in DMEM containing excess cold methionine/
cysteine. Following chase, cells were lysed in PBS containing 1% NP-
40 and protease inhibitors (Roche, http://www.roche.com). The cell
lysate was pre-cleared with protein A/G agarose beads overnight and
incubated with 3 lg of antibody for 1 h, followed by 1 h with
protein A/G beads. Immunoprecipated proteins were washed ﬁve
times with 1% NP-40 in PBS. All samples were boiled in Laemmli
buffer and analyzed by SDS-PAGE gel electrophoresis. Gels were
ﬁxed, dried, and exposed to Kodak (http://www.kodak.com) BioMax
MR ﬁlm. Western blotting was accomplished using the Western-
Breeze Chemiluminescent Detection System (Invitrogen) following
semi-dry transfer to PVDF membranes (Millipore, http:// www.milli-
pore.com).
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